CCO Management Series
Cardiovascular Risk Factors and Metabolic Complications in Patients Receiving HAART
Pathogenesis of Metabolic Abnormalities in HIV-Infected Patients
|
Module 1 of 3
|
Program Director:
John P. Phair, MD
- Judith S. Currier, MD, MSc
|
|
|
 Topics covered include:
- Introduction
- Overview of Lipid Abnormalities
- Impact of HIV Infection on Lipids: Data from the Pre-HAART Era
- Relative Impact of HIV and Therapy: Data from MACS
- Protease Inhibitors and Lipid Metabolism
Learning Objectives
Upon completion of this activity, participants should be able to:
Understand the relative impact of HIV itself and antiretroviral therapy on lipid parameters Describe the possible relevance of genetic predisposition to lipid changes associated with the use of antiretroviral therapy Review the mechanisms by which antiretroviral agents may affect lipid metabolism
|
Epidemiology and Evaluation of Cardiovascular Risk Factors in HIV-Infected Patients
|
Module 2 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Epidemiology of Dyslipidemia
- Impact of Antiretrovirals on Lipids
- Impact of Antiretrovirals on Lipids (Continued)
- Impact of Antiretrovirals on Lipids (Continued)
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the impact of HIV infection itself and antiretroviral therapy on lipid levels Describe the results of epidemiologic studies evaluating the incidence of cardiovascular disease in HIV-infected patients List factors that are classically associated with increased risk of cardiovascular disease, and review their prevalence among HIV-infected patients
|
Individualizing HIV Care in Light of Cardiovascular Risk
|
Module 3 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Significance of Cardiovascular Disease Among HIV-Infected Patients
- Considerations When Initiating Antiretroviral Therapy
- Evaluating Traditional Cardiovascular Risk Factors
- Implications of Cardiovascular Risk Assessment for Antiretroviral Selection
Learning Objectives
Upon completion of this activity, participants should be able to:
Review studies evaluating the association between specific therapies and cardiovascular risk Describe strategies for reducing cardiovascular risk in HIV-infected patients Understand factors that are associated with cardiovascular risk in HIV-infected patients
|
Interactive Case Challenges
Management of Hyperlipidemia in a Patient Receiving a Triple-Class Regimen
Program Director:
John P. Phair, MD
- Judith S. Currier, MD, MSc
|
|
|
 Test your ability to provide optimal clinical management for a treatment-naive patient in whom therapy is indicated, and to manage first virologic failure. Learning Objectives
Upon completion of this activity, participants should be able to:
Review current recommendations on the management of hyperlipidemia in HIV-infected patients Describe the expected effects of stains and fibrates in HIV-infected patients Discuss strategies for modifying antiretroviral regimens to ameliorate hyperlipidemia
|
Management of Dyslipidemia in a Highly Experienced PI-Treated Patient
Program Director:
John P. Phair, MD
|
|
Evaluate the optimal use of statins and fibrates in a man with limited antiretroviral options. Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the relative merits of different lipid-lowering agents Identify lipid-lowering agents that are contraindicated in patients receiving protease inhibitors Describe possible interventions to address hyperlipidemia in HIV-infected patients
|
Management of an African Man with Advanced HIV Infection and Significant Cardiovascular Risk
Program Director:
John P. Phair, MD
|
|
Develop strategies to minimize the risk of CVD in a treatment-naive patient. Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the drug-drug interaction between tenofovir DF and atazanavir Discuss the appropriate management of common adverse effects of NNRTI therapy Outline the relative merits of different first-line antiretroviral regimens in patients with significant cardiovascular risk factors
|
Interactive Tools and Resources
Impact of Different Interventions on Cardiovascular Risk in HIV-Infected Patients
 |
|
An interactive resource that illustrates the impact of different interventions on the 10-year risk of cardiovascular disease in hypothetical patients with different baseline characteristics.
Format: Adobe Flash | File size: 47 KB
|
Algorithm for Management of Patients with Hyperlipidemia During PI-based Therapy
 |
|
An interactive flowchart offering options for the clinical care of HIV-infected patients who experience protease inhibitor-associated hyperlipidemia.
Format: Adobe Flash | File size: 15 KB
|
Animations
Impact of HIV Infection and Antiretroviral Therapy on Lipid Levels: Data from MACS
 |
|
Review findings from the Multicenter AIDS Cohort Study regarding changes in lipid levels following HIV seroconversion, and the subsequent impact of HAART
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash | File size: 228 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|